/

MRKR

Marker Therapeutics, Inc.Closed

0.9249−0.09 −8.43%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.03

Prev close

1.01

Day range

0.91001.03

52-week range

0.84002.46

Volume

175.20K2.58×

Mkt cap

15.42M

P/E ttm

—

Fwd P/E

-1.75

EPS ttm

-0.4200

Div yield

0.00%

Earnings

—

From 52w high

−62.40%

Price Chart

Yahoo Finance · delayed

MRKROct 13, 2026O 1.0300H 1.0300L 0.9100C 0.9200−0.0900 (−8.91%)Vol 175.20K

SMA 501.1828
SMA 2001.4161

1Y change −9.80% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MRKR Marker Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −8.91%
1 month: −20.00%
3 months: −36.11%
6 months: −42.14%
Year to date: −38.26%
1 year: −9.80%

Valuation & ownership

Market cap: 15.42M
Enterprise value: 4.09M
P/E (ttm): —
Forward P/E: -1.75
PEG ratio: —
Price / book: 1.27
Price / sales (ttm): 4.35
EV / EBITDA: —
EPS (ttm): -0.4200
EPS (forward): -0.5300
Beta (5y monthly): 1.53
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 16.67M
Float: 13.74M
Short % of float: 1.25%
Short ratio (days): 2.51
Held by insiders: 5.49%
Held by institutions: 23.80%
Avg volume (3m): 67.89K
50-day average: 1.19
200-day average: 1.42
52-week change: −9.80%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.1
vs 50-day SMA: −22.22%
vs 200-day SMA: −35.03%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.02%
Realised vol (20d, ann.): 59.9%
From 52-week high: −62.60%
From 52-week low: +9.52%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

7.87

+750.54% implied

Low 5.60Median 8.00High 10.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

Buy / hold / sell counts

DES

About Marker Therapeutics, Inc.

Yahoo Finance profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Houston, TX, United States
Website: markertherapeutics.com
Officers: Dr. Juan F. Vera M.D. Co-Founder, CEO, President, Treasurer, Secretary & Director
Ms. Elizabeth Donnelly Director of Administration
Dr. Maria-Bernadette Madel Ph.D. Director of Corporate Operations & External Communications

SEAS

Seasonality · MRKR

2007–2026 · monthly returns

Strongest month Jun +20.20%Weakest month Aug −11.83%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	7.4	-7.5	-12.2	12.3	7.5	-6.4	-23.1	17.7	-19.5	-13.6			−37.9%
2025	-40.8	-16.8	-19.6	-3.3	31.1	-1.9	-8.5	-33.6	-4.3	11.2	25.3	20.2	−52.1%
2024	-15.6	-21.8	18.5	-5.8	-4.4	40.3	-9.9	-26.2	-21.9	43.6	-13.6	-11.1	−43.5%
2023	3.7	-22.5	-67.3	18.3	111.9	74.2	62.9	11.3	-19.2	-47.1	15.0	99.3	+103.7%
2022	-35.8	-37.7	15.8	-22.7	-11.8	10.0	-3.0	-3.1	19.4	18.9	-31.8	-10.0	−71.6%
2021	32.4	26.0	-7.4	14.3	13.7	-4.1	-25.1	-5.3	-14.6	-13.0	-19.7	-19.5	−34.5%
2020	-10.1	-4.6	-23.1	45.3	-17.8	-8.8	-2.9	-10.4	-16.7	-9.3	25.0	-14.7	−49.7%
2019	-4.7	17.6	6.1	-20.0	6.2	41.2	-41.8	12.1	-1.2	-24.9	-13.0	-13.8	−48.1%
2018	-0.5	-16.7	4.0	-21.6	94.7	82.8	-25.7	23.0	5.0	-0.3	-21.7	-21.4	+41.6%
2017	7.7	7.9	-0.4	-6.5	-7.1	-0.5	-16.2	0.0	-7.4	0.3	-7.9	41.0	+1.0%
2016	-1.7	8.5	6.2	-5.9	-9.4	-12.1	-9.8	0.0	21.2	-25.3	-9.2	-14.5	−46.1%
2015	-35.7	22.2	-4.5	-4.8	65.0	190.9	-45.8	-28.8	67.6	-3.2	-1.7	1.7	+114.3%
2014	0.0	135.0	-20.2	-13.9	-52.0	24.5	-25.4	-20.1	-45.2	-39.7	2.6	-28.2	−86.0%
2013	25.0	-33.3	0.0	-60.0	25.0	-40.0	-33.3	-50.0	0.0	100.0	50.0	-33.3	−83.3%
2012	6.7	0.0	-6.3	26.7	-26.3	-14.3	-25.0	33.3	0.0	-8.3	-18.2	33.3	−20.0%
2011	0.0	0.0	64.7	-10.7	-28.0	38.9	4.0	-23.1	-25.0	46.7	4.5	-34.8	−11.8%
2010	27.3	-23.2	-41.9	16.0	-13.8	-44.0	21.4	-41.2	40.0	-7.1	92.3	-32.0	−61.4%
2009	-25.0	0.0	33.3	25.0	0.0	-20.0	175.0	4.5	-20.0	8.7	-50.0	-12.0	+10.0%
2008	71.4	-41.7	-28.6	140.0	29.2	-3.2	-40.0	-33.3	-50.0	-33.3	0.0	0.0	−71.4%
2007	77.8	-31.3	27.3	7.1	-20.0	30.0	74.4	-33.8	0.0	-22.2	-28.6	-44.0	−37.8%

INSD

Insider Activity · MRKR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Dec 22, 2024	Elms Steven ADirector	Purchase at price 3.20 per share.	11.1K	$35.47K
Dec 22, 2024	New Enterprise Associates 16, L.P.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 3.20 per share.	554.3K	$1.77M

13F

Investors Holding MRKR

latest 13F filings of 29 followed managers

Investors holding MRKR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$366.7K	0.00%	249.42K	+42%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

MRKR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MRKR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Marker Therapeutics, Inc.

Seasonality · MRKR

Insider Activity · MRKR

Congress Trades · MRKR

Investors Holding MRKR

Investors Holding MRKR

Congress Trades · MRKR

Seasonality · MRKR

Insider Activity · MRKR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Marker Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News